Gene Discovery Firm Affymetrix Signs Three-Year Pact With Eli Lilly
September 09, 1998 2:45 PM
SANTA CLARA, Calif. -(Dow Jones)- Affymetrix Inc.
said Wednesday it signed a three-year pact granting Eli
Lilly & Co. broad access to its line of tools used in
genetic discovery.
Affymetrix has developed a system called GeneChip,
which is used to analyze and manage genetic information
to improve diagnosis and treatment of disease.
GeneChip packs thousands of DNA probes on a wafer
and features instruments to process and interpret the
genetic data. Affymetrix uses the system and related
technology to facilitate the analysis of tissue samples.
Terms of the pact, which is a volume discount pricing
agreement designed for large research organizations,
weren't disclosed.
Affymetrix (AFFX) said Eli Lilly will monitor gene
expression for use in its research and development
activities.
Other Affymetrix customers include American Home
Products Corp, Roche Holding AG, Glaxo Wellcome
PLC, Hoechst AG, Merck & Co., Novartis AG,
Warner Lambert Co. and Pfizer Inc.
Copyright (c) 1998 Dow Jones & Company, Inc.
All Rights Reserved.
smartmoney.com
|
